These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27433783)

  • 21. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
    Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.
    Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309
    [No Abstract]   [Full Text] [Related]  

  • 23. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Kodali N; Bhattaru A; Blanchard I; Sharma Y; Lipner SR
    Melanoma Res; 2024 Oct; 34(5):419-428. PubMed ID: 38564430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
    Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
    J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
    [No Abstract]   [Full Text] [Related]  

  • 29. Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma.
    Sheen YS; Chu CY
    Br J Dermatol; 2021 Mar; 184(3):390-391. PubMed ID: 33448329
    [No Abstract]   [Full Text] [Related]  

  • 30. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
    Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.
    Gutiérrez-Castañeda LD; Nova JA; Tovar-Parra JD
    Melanoma Res; 2020 Feb; 30(1):62-70. PubMed ID: 31274706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
    Del Regno L; Louveau B; Battistella M; Sadoux A; Baroudjian B; Delyon J; Serror K; Allayous C; Lebbe C; Mourah S; Jouenne F
    Br J Dermatol; 2020 May; 182(5):1281-1283. PubMed ID: 31675434
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules.
    de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF
    Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.